Hexosamines have been hypothesized to mediate aspects of glucose sensing and toxic effects of hyperglycemia. For example, insulin resistance results when the rate-limiting enzyme for hexosamine synthesis, glutamine:fructose-6-phosphate amidotransferase (GFA), is overexpressed in muscle and adipose tissue of transgenic mice. The glucose infusion rates required to maintain euglycemia at insulin infusion rates of 0.5, 2, 15, and 20 mU/kg⅐min were 39 -90% lower in such transgenic mice, compared with their control littermates (P Յ 0.01). No differences were observed in hepatic glucose output, serum insulin levels, or muscle ATP levels. Uptake of 2-deoxyglucose, measured under conditions of hyperinsulinemia, was significantly lower in transgenic hindlimb muscle, compared with controls (85.9 Ϯ 17.8 vs. 166.8 Ϯ 15.1 pmol deoxyglucose/g⅐min). The decrease in glucose uptake by transgenic muscle was associated with a disruption in the translocation of the insulin-stimulated glucose transporter GLUT4. Fractionation of muscle membranes on a discontinuous sucrose gradient revealed that insulin stimulation of control muscle led to a 28.8% increase in GLUT4 content in the 25% fraction and a 61.2% decrease in the 35% fraction. In transgenic muscle, the insulin-stimulated shifts in GLUT4 distribution were inhibited by over 70%.
S
KELETAL MUSCLE is responsible for the majority of insulin-stimulated glucose uptake (1) . Insulin resistance and decreased insulin-stimulated glucose use are hallmarks of type 2 diabetes mellitus and can be seen as a result of hyperglycemia in type 1 diabetes, as well (2) (3) (4) . The mechanism of these effects is unknown. The hexosamine biosynthetic pathway has been shown to play a role in some of the adverse regulatory effects of hyperglycemia (5) . For example glucosamine infusion in rats causes insulin resistance in skeletal muscle by inhibiting insulin's ability to stimulate the translocation of the insulin-stimulated glucose transporter (GLUT4) from intracellular pools to the plasma membrane (6, 7) . Glucosamine also causes insulin resistance for glycogen synthesis (8) .
We have previously demonstrated that overexpression of glutamine:fructose-6-phosphate amidotransferase (GFA), the first and rate-limiting enzyme of the hexosamine biosynthetic pathway, in muscle and adipose tissue of transgenic mice leads to increased hexosamine levels and causes insulin resistance in vivo (9) . The current study was undertaken to explore further the relationship of the defects in glucose uptake seen in this transgenic model to those of type 2 diabetes, in terms of the mechanism for the decreased glucose uptake and its reversal by the peroxisome proliferator-activated receptor (PPAR)␥ agonist troglitazone. The results are consistent with the hypothesis that excess glucose metabolism through the hexosamine pathway may be responsible for the diminished insulin sensitivity and defective glucose uptake that are seen in hyperglycemia. Furthermore, the defects in glucose transport seen in the transgenic mice are very similar to those seen in human type 2 diabetes.
Materials and Methods Animals
The creation of transgenic mice overexpressing human GFA in skeletal muscle through the use of the GLUT4 promoter/enhancer has been previously described (9) . All animals used for experiments were 3-to 6-month-old littermates resulting from the breeding of a single line of GFA overexpressing mice. Heterozygote transgenic animals, bred on a C57Bl6 background, were crossed to nontransgenic C57Bl6 mice, resulting in litters consisting of approximately 50% heterozygote transgenic animals and an equal number of nontransgenic littermates that were used as controls. Animals were housed in a room maintained at 23 C with a fixed 12-h light, 12-h dark cycle and given free access to rat chow and water. Experimental protocols were approved by the Animal Use Committee of the Veterans Affairs Medical Center.
To examine the effects of troglitazone, age-and weight-matched heterozygote transgenic and control mice were treated daily for 30 days with either 10 mg troglitazone mixed in 100 mg of peanut butter or with 100 mg of peanut butter alone. Five mice in each group were then studied by the hyperinsulinemic euglycemic clamp technique, after which the animals were killed and their hindlimb muscles harvested for analysis of GFA activity and uridine 5Ј-diphosphate (UDP)-N-acetylglucosamine levels.
Determination of glucose infusion rate and hepatic glucose output (HGO)
All experiments were performed in awake, weight-matched, nonsedated transgenic and littermate control mice using a euglycemic clamp technique previously described (9) . Catheters were implanted into the right internal jugular vein. The animals were allowed to recover from surgery for 1 day and were then fasted 18 h before the experiment. [3- 3 H]glucose (New England Nuclear, Boston, MA) was infused throughout the clamp experiment to determine the glucose turnover rate. A priming dose of 0.33 Ci (19 Ci/mmol) in 11.2 l saline (0.9%) was infused, followed by continuous infusion at a rate of 0.08 Ci/min (2.5 l/min) for the duration of the experiment. Animals were infused with recombinant human insulin (HumulinR, Eli Lilly & Co., Indianapolis, IN) at a rate of 2, 15, or 20 mU/kg⅐min, while 50% dextrose was infused by a variable infusion pump (Harvard Apparatus Inc., South Natick, MA). Whole-blood samples (3 l) were collected every 5-10 min from tail bleeds and measured by the glucose oxidase method (Glucometer Elite, Bayer Corp., Tarrytown, NY). Blood glucose concentrations and glucose infusion rates were clamped at steady state for a minimum of 20 min. Serum samples were then taken for calculating insulin levels and HGO. Insulin concentrations were measured by RIA using porcine standards (Binax, Portland, ME); this assay detects both human and rodent insulin. The rate of glucose appearance (or glucose turnover rate) was calculated by dividing the [3- 3 H]glucose infusion rate (dpm/kg⅐min) by the mean serum glucose specific activity (dpm/mg glucose). The rate of HGO was calculated by subtracting the glucose infusion rate from the glucose turnover rate. Isotopically determined glucose disposal rates (GDRs) were calculated by subtracting the HGO from the glucose infusion rate.
Determination of skeletal muscle glucose uptake, GFA activity, UDP-N-acetylglucosamine levels, and ATP levels
Mice were catheterized, allowed to recover from surgery the following day, and fasted 18 h before the experiment. With no priming dose or continuous infusion of 3 H-glucose, the animals were infused with recombinant human insulin at a rate of 20 mU/kg⅐min, while 50% dextrose was infused by a variable infusion pump. After the animals' serum glucose levels were stabilized (minimum of 10 min), a bolus injection of 2-deoxy-d- [1- 3 H]glucose ([ 3 H]2-DOG) and [U-14 C]sucrose (200 pmol of each, 11 Ci/mmol and 667 mCi/mmol, respectively; Amersham, Arlington Heights, IL) was administered. The clamp was continued for an additional 10 min, after which time the animal was killed, blood was collected, and the triceps surae group from each hind limb was extracted, weighed, and frozen in liquid nitrogen. The triceps surae group was selected because its muscle fiber composition is representative of total hindlimb fiber composition (10) . Muscle samples were processed as described by Brozinick et al. (11) . Muscle samples were homogenized in 2 ml of 10% trichloroacetic acid (TCA) at 4 C. Muscle homogenates and serum samples (20 l serum with 40 l 10% TCA) were centrifuged in a microcentrifuge at 14,000 ϫ g for 10 min. Radioactivity in duplicate samples of the muscle and serum supernatants (300 l of muscle supernatant and 15 l of the serum supernatant) was measured by scintillation counting. The accumulation of intracellular [ 3 H]2-DOG was calculated by subtracting the amount in the extracellular space from the total in the muscle samples, using the facts that glucose and sucrose will both diffuse in the extracellular space but sucrose will not be transported into cells. Thus, intracellular glucose ϭ total muscle glucose Ϫ extracellular glucose, where extracellular glucose ϭ (serum glucose) ⅐ (muscle sucrose) ⅐ (serum sucrose) Ϫ1 . GFA activity and UDP-N-acetylglucosamine levels were assayed as described (9) . ATP measurements were performed on triceps surae group muscle that had been homogenized and sonicated in 12% TCA, using a kit from Sigma Chemical Co. (St. Louis, MO), based on the principle that ATP levels can be determined by measuring the change in absorbance at 340 nm that takes place when NADH is oxidized to NAD.
Membrane subfractionation of skeletal muscle
Hindlimb muscle from transgenic and control mice that had been either fasted (basal) or subjected to a hyperinsulinemic-euglycemic clamp (insulin-stimulated) was rapidly isolated, frozen in liquid nitrogen, and stored at Ϫ80 C. The muscle tissue was placed in Tris buffer (20 mm Tris-base, 0.25 m sucrose, 0.2 mm EDTA, 40 mm phenylmethylsulfonylfluoride, 5 g/ml leupeptin, 5 g/ml aprotinin, and 1 g/ml pepstatin), pH 7.4, at 4 C. Subfractionation of muscle membranes was as described by Baron and colleagues (7), whose procedure was modified from that of Klip and colleagues (12, 13) . The muscle was homogenized with a Polytron tissue disrupter (Brinkmann Instruments, Inc., Westbury, NY) using five 5-sec bursts at a setting of 5 and then with 10 up-and-down strokes of a motor-driven Teflon pestle in a glass homogenization tube (Thomas Scientific, Philadelphia, PA). The homogenate was centrifuged at 1,000 ϫ g for 10 min, and the supernatant was saved. The resulting pellet was resuspended in the buffer and rehomogenized with the glass homogenization tube and Teflon pestle (as described above), and the supernatant was combined with the first supernatant and centrifuged at 9,000 ϫ g for 10 min. The resulting supernatant was then centrifuged at 190,000 ϫ g for 60 min; the resuspended pellet constituted the total postnuclear membrane fraction. These membranes were then applied to a discontinuous sucrose gradient containing 25%, 30%, and 35% sucrose (wt/vol) solutions and was centrifuged at 40,000 ϫ g for 16 h in a swinging-bucket rotor. Membranes were collected atop each of the sucrose gradients, resuspended in Tris buffer, pelleted by centrifugation at 190,000 ϫ g for 60 min, and resuspended in Tris buffer. All suspensions of membrane subfractions were kept at Ϫ80 C for subsequent immunoblot analyzes. To monitor membrane subfractionation, we measured 5Јnucleotidase activity using the method of Avruch and Wallach (14) , oubain-inhibitable Na ϩ /K ϩ ATPase activity, as described previously (15), and immunoreactive phospholemman (16, 17) as markers for sarcolemma in total membranes and membrane subfractions.
Immunoblot analysis
Thirty micrograms of membrane protein were solubilized in Laemmli sample buffer (18) , electrophoresed by SDS-PAGE on 1.5-mm slab gels, and transferred to nitrocellulose filters (19) . Immunological detection of GLUT4 was accomplished as previously described (20) . Nitrocellulose filters were incubated with affinity-purified rabbit antiserum (1:1000 dilution) specific for the COOH-terminal segment (12 amino acids) of rat GLUT4 (21) (East Acres Biologicals, Southbridge, MA), followed by 125 I-protein A. Detection of phospholemman was accomplished by incubating filters with affinity-purified rabbit antiserum raised against canine phospholemman (16, 17) (a gift of Dr. Larry Jones, Indiana University), followed by 125 I-protein A. Quantitation of GLUT4 levels was accomplished by excising the GLUT4 band and measuring radioactive counts. Phospholemman was measured with scanning densitometry (Bio-Rad, Richmond, CA) of autoradiographs. For measurement of both GLUT4 and phospholemman, background measurements were subtracted from signal, to obtain relative levels of the immunoreactive protein; and measurements were consistently in the range where the relationship between increasing amounts of membrane protein and signal was linear.
Statistical analysis
All values are presented as mean Ϯ sem. Student's t test was performed for comparisons of means between two groups.
Results

Glucose infusion rates and HGO during the euglycemic clamp
Nonsedated weight-matched transgenic and control littermates (22.5 Ϯ 1.1 and 22.2 Ϯ 1.6 g, respectively) were clamped at a blood glucose of 8.3 Ϯ 0.2 mm while being infused with insulin at a constant rate of 0.5, 2, 15, or 20 mU/kg⅐min. At the end of the clamp, the glucose infusion rate was calculated, and blood was collected to calculate HGO and determine insulin levels. HGO was not determined for mice clamped at the insulin infusion rate of 0.5 mU/ kg⅐min, because of experimental limitations. Calculation of the glucose infusion rates shows that transgenic mice required a lower level of infused glucose to maintain similar blood glucose levels, compared with their control littermates (Fig. 1A) . The transgenic mice required a 90, 45, 39, and 40% reduction of the glucose infusion rate to maintain euglycemia during the clamp at insulin infusion rates of 0.5, 2, 15, and 20 mU/kg⅐min, respectively. HGO did not differ between transgenic and control mice under basal conditions and during the euglycemic clamp with insulin infusion rates of 2, 15, and 20 mU/kg⅐min (Fig. 1B) . Serum insulin levels also did not differ between transgenic and control mice during the euglycemic clamp (Fig. 1C) .
Decreased glucose uptake by skeletal muscle during the hyperinsulinemic-euglycemic clamp
Weight-matched transgenic and control mice (23.9 Ϯ 2.1 and 25.4 Ϯ 2.4 g, respectively) were clamped at a blood glucose of 7.9 Ϯ 0.7 mm during constant insulin infusion of 20 mU/kg⅐min, without the priming dose or continual infusion of [ Fig. 2A shows the GDRs for the transgenic and control mice during the clamp studies. Transgenic mice had a GDR that was 35% lower than that of the control mice. Fig. 2B shows that [ 3 H]2-DOG uptake by skeletal muscle was decreased by 49% in transgenic mice, compared with control littermates.
ATP levels in muscle were also assayed after the hyperinsulinemic clamp studies. There was no significant difference in the ATP level in transgenic muscle (0.70 Ϯ 0.18 mol/g muscle), compared with control muscle (0.68 Ϯ 0.13 mol/g muscle, n ϭ 6 per group).
In vitro studies of skeletal muscle GLUT4 distribution
Hindlimb skeletal muscle from weight-matched, fasted transgenic and control mice (26.4 Ϯ 0.8 and 25.2 Ϯ 1.8 g, respectively) was harvested either in the basal state or after a clamp at 9.3 Ϯ 0.3 mm glucose with an insulin dose of 20 mU/kg⅐min. The muscle was subjected to a membrane subfractionation protocol employing centrifugation on discontinuous sucrose density gradients. GLUT4 levels in the various subcellular fractions were quantitated by PAGE of membrane proteins, followed by immunoblot analysis. The results of these analyzes are shown in Table 1 . Total GLUT4 content did not differ between transgenic and control muscle. GLUT4 distribution also did not differ in the basal state between transgenic and control muscle, but differences did emerge with insulin stimulation. After insulin stimulation of control muscle, GLUT4 distribution increased in the 25% fraction by 28.8 Ϯ 1.9% (P Ͻ 0.05) and decreased in the 35% fraction by 61.2 Ϯ 1.1% (P Ͻ 0.001). Insulin led to smaller and statistically insignificant changes in GLUT4 distribution in transgenic muscle, increasing in the 25% fraction by 8.5 Ϯ 5.0% and decreasing in the 35% fraction by 7.5 Ϯ 5.3%. The differences in insulin-induced GLUT4 redistribution between the transgenic and control muscles were significant in the 25% fractions (P Ͻ 0.05) and in the 35% fractions (P Ͻ 0.001). No differences, comparing either transgenic to control or insulin-stimulated to basal, were noted in the GLUT4 content in the 30% fraction. Two sarcolemmal markers, 5Ј-nucleotidase activity and immunoreactive phospholemman, were measured and found to be greatest in the 25% fraction (data not shown). These data are consistent with previous studies and have been interpreted to reflect insulin-mediated translocation of GLUT4 from intracellular membranes in the 35% sucrose fraction to sarcolemma retrieved in the 25% fraction (7, 12, 13).
Reversal of insulin resistance for glucose disposal by troglitazone
Nonsedated weight-matched transgenic and control mice (25.6 Ϯ 1.8 and 24.0 Ϯ1.5 g, respectively) were treated with troglitazone (10 mg/day for 30 days) or vehicle. The mice were then subjected to a hyperinsulinemic euglycemic clamp with insulin (20 mU/kg⅐min) and 50% glucose infusion. As shown in Fig. 3 , the decrease in glucose disposal in the transgenic animals was completely reversed by troglitazone treatment (P Ͻ 0.001, n ϭ 5/group). The drug was without a significant effect in the control animals.
To determine whether the effect of troglitazone was distal to the generation of hexosamines, the levels of GFA and UDP-N-acetylglucosamine were next measured in the muscle of the control and drug-treated animals (Fig. 4) . As had been previously demonstrated, GFA activity was higher in the transgenic animals, compared with controls (P Ͻ 0.05 for the nondrug-treated animals, P Ͻ 0.03 for the drug-treated animals). However, troglitazone had no effect on GFA activity, either in control or transgenic animals. Similarly, the principal end product of hexosamine biosynthesis UDP-Nacetylglucosamine was higher in the transgenic animals (P Ͻ 0.02) but was also unaffected by troglitazone treatment.
Discussion
The hexosamine biosynthetic pathway has been hypothesized to be involved in mediating some of the toxic effects of hyperglycemia (5, 22). Garvey et al. (23) showed that insulin-stimulated glucose uptake in primary cultures of adipocytes could be inhibited by treating the cells with 20 mm glucose for 24 h. They further determined that the cause of this insulin resistance was an inhibition of GLUT4 translocation from intracellular vesicles to the plasma membrane, with no change in GLUT4 protein levels. Through a series of experiments, Marshall et al. (5) subsequently demonstrated that this glucose-induced inhibition of insulin-stimulated glucose uptake was caused by increased flux of glucose into hexosamine biosynthesis: glucose-induced reductions in glucose uptake could be blocked by inhibitors of hexosamine synthesis, and this blockade could be bypassed, at higher potency, by glucosamine, which enters the hexosamine pathway after being phosphorylated by hexokinase to form glucosamine-6-phosphate. Subsequently, infusion of glucosamine into whole animals was found to cause a decrease in insulin's ability to stimulate glucose uptake in vivo (6, 7) ; in the latter study, muscle GLUT4 translocation was inhibited by glucosamine, with no change in GLUT4 protein levels (7) . All of these studies have led to the hypothesis that some of the adverse effects of hyperglycemia, and perhaps the pathogenesis of type 2 diabetes itself, may be linked to hexosamine biosynthesis. The current studies strengthen this link by demonstrating the similarity of hexosamine-induced insulin resistance to type 2 diabetes. In both conditions, skeletal muscle glucose uptake is impaired, secondary to defective insulin-stimulated translocation of GLUT4, and both conditions can be treated with agonists of PPAR␥, such as troglitazone.
Early strategies to investigate the effects of increased hexosamine synthesis and its effects on insulin-stimulated glu- cose disposal in vivo have involved infusions with glucose or glucosamine. Glucosamine affects other tissues involved in glucose homeostasis, specifically impairing the suppression of HGO by hyperglycemia (24) and impairing insulin secretion (25) . Furthermore, at high concentrations, glucosamine has effects not directly related to increases in hexosamine flux. For example, glucosamine treatment can deplete cellular ATP (26) and directly affect enzymes such as glucokinase (24) . Thus, to avoid the multiple effects of infusing animals with glucosamine and to implicate the hexosamine pathway more directly in the regulation of insulin-stimulated glucose uptake in skeletal muscle, our laboratory has taken a tissuespecific transgenic approach to investigate the effects of increased hexosamine biosynthesis. By overexpressing the rate-limiting enzyme for hexosamine synthesis GFA in the target tissues of insulin-stimulated glucose disposal, we sought to investigate the effects of increased hexosamine biosynthesis in muscle and adipose tissue, without the additional effects known to be caused by treatment with nonphysiologic concentrations of glucosamine (24 -26) . With approximately a 2-fold increase in skeletal muscle GFA activity in the transgenic animals (9), total cellular glucose flux into the hexosamine pathway would be estimated to increase from approximately 2% to only 4 -6%, and thus should neither significantly alter glucose availability for oxidative or nonoxidative metabolism nor cause significant changes in cellular ATP pools.
Overexpression of GFA in skeletal muscle and adipose tissue of transgenic mice did result in the inhibition of insulin-stimulated glucose disposal in intact animals (9) . These results are confirmed and expanded in the current study, with the demonstration that the transgenic mice are insulin resistant, compared with their nontransgenic littermates, over a wide range of insulin doses, with no difference in HGO. More importantly, we demonstrate directly that this peripheral insulin resistance can be accounted for by a decrease in glucose uptake, as determined by [ 3 H]2-DOG uptake during a hyperinsulinemic clamp.
The decrease in 2-DOG uptake in muscle overexpressing GFA is paralleled by a significant defect in GLUT4 translocation after insulin stimulation. Skeletal muscle from animals infused with glucosamine has also been shown to be insulin resistant, primarily because of an inhibition of GLUT4 translocation (7). Although we previously reported a decrease in GLUT4 protein (but not messenger RNA) levels in these transgenic mice (9), the current study demonstrates that skeletal muscle GLUT4 protein levels, assessed by immunoblotting, did not differ between the transgenic and control mice. The reasons for this discrepancy are not clear. The previous immunoblots for GLUT4 were performed using a different antibody and on mice whose genetic background was in flux, because they were being back-bred onto a C57Bl6 background to facilitate the detection of diabetes-and obesityrelated phenotypes. The current study was performed using mice that had been bred on the C57Bl6 background for more than 6 generations. Regardless of the reasons for the discrepancy, the current evidence shows clearly that the translocation defect can account for the defect in glucose uptake. Thus, there seems to be a common mechanism by which diabetes, glucosamine infusion, or overexpression of GFA cause insulin resistance to glucose uptake in skeletal muscle.
Further evidence for the similarity of hexosamine-induced insulin resistance to human type 2 diabetes is provided by reversal of the insulin resistance in the transgenic animals by troglitazone. The mechanism of action of PPAR␥ agonists is still unknown. Although the most parsimonious explanation of the current results would involve a direct effect of the drug on skeletal muscle, there is controversy about the possible contribution of muscle to troglitazone action. Several recent studies have been able to demonstrate PPAR␥ messenger RNA and troglitazone action in skeletal muscle and in muscle-derived cells (27) (28) (29) (30) (31) . Furthermore, PPAR␥ levels in muscle have been reported to be altered in insulin-resistant states (32) , and there is rationale for PPAR␥ action in muscle, given the regulation by PPAR␥ of genes involved in fatty acid oxidation by muscle (33) . At this time, however, we cannot rule out an indirect effect of troglitazone, such as an alteration in delivery of fuel or regulatory factors, from fat to muscle, that reverses the hexosamine-induced defect.
The results on the effects of troglitazone are at variance with those of a previous study wherein glucose-, but not glucosamine-induced insulin resistance could be reversed by troglitazone (34) . However, the latter study employed an acute infusion with a high concentration of glucosamine, and whether this acute model is analogous to chronic diabetes or chronically increased hexosamine flux is not known. In the absence of information on the dose responsiveness of the insulin resistance for glucosamine or troglitazone, the significance of the previously published negative data is unclear. Furthermore, the appropriateness of using acute glucosamine exposure to study hexosamine-induced insulin resistance has been raised in a recent publication, indicating that some of the observed effects on glucose uptake in glucosamine infused animals might be accounted for by decreased ATP levels (26) . This was not the case in the current study, because the transgenic animals did not exhibit decreased muscle ATP levels. This result was not surprising, given the relatively small increase in glucose flux into the hexosamine pathway achieved by overexpressing GFA. The results do illustrate, however, the advantages of studying the effects of hexosamine flux in the transgenic model system, as opposed to acute exposure of cells and animals to high concentrations of glucosamine.
The lack of an effect of troglitazone on GFA and UDP-Nacetylglucosamine levels argues that the effect of that drug in reversing insulin resistance is distal to the generation of hexosamines. How increased hexosamine flux or troglitazone exerts these effects on glucose uptake is unknown. The final product of hexosamine synthesis, UDP-N-acetylglucosamine, is a substrate for protein glycosylation, both Nand O-linked. Recently, O-linked glycosylation has been hypothesized to be a regulatory modification, analogous to phosphorylation, that may play a role in mediating the assembly of regulatory protein complexes (35) . Unlike N-linked glycosylation, O-linked glycosylation is dynamic and has a rapid turnover rate. Identification of the O-glycosylation sites on c-myc (36) and RNA polymerase suggests a possible reciprocal functional relationship of O-glycosylation with phosphorylation. Synthetic peptides corresponding to sequences of glycogen synthase have been shown to be effective substrates for O-glycosylation (35) . Thus, both transcriptional and posttranslational changes, mediated by Oglycosylation, are candidate mechanisms by which cells use hexosamine synthesis as a glucose-sensing mechanism (35) (36) (37) .
In conclusion, we have demonstrated that overexpression of GFA, the rate-limiting enzyme in hexosamine synthesis, in muscle and adipose tissue of transgenic mice, causes insulin resistance over a wide range of insulin doses. Furthermore, this insulin resistance is directly demonstrated to be caused by a decrease in glucose uptake in skeletal muscle, secondary to an inhibition of GLUT4 translocation from intracellular vesicles to the plasma membrane. The thiazolidinedione troglitazone reverses this insulin resistance by acting at a point distal to the generation of hexosamines. Thus, the similarities revealed between type 2 diabetes and hexosamine-induced insulin resistance are striking. We have hypothesized that the hexosamine pathway serves the as a satiety sensor for insulin-dependent tissues (22) ; and these studies lend further support to the hypothesis that increased glucose flux through the hexosamine pathway mediates adverse effects of hyperglycemia, as well. Further characterization of these mice should be instrumental in clarifying the role that hexosamines and hexosamine synthesis play in cellular sensing of glucose and the responses to hyperglycemia.
